Document Detail

Haemate P/Humate-P for the treatment of von Willebrand disease: considerations for use and clinical experience.
MedLine Citation:
PMID:  18786009     Owner:  NLM     Status:  MEDLINE    
von Willebrand disease (VWD) is a heterogeneous bleeding disorder with symptoms in affected patients ranging from mild effects to potentially devastating haemorrhagic events. Desmopressin (DDAVP) and von Willebrand factor/factor VIII (VWF/FVIII) concentrates are the principal treatments. Haemate P/Humate-P is an intermediate-purity VWF/FVIII concentrate with extensive clinical experience in VWD. This concentrate has been shown to correct haemostatic defects of VWD, with efficacy ratings of good/excellent in nearly all patients treated for bleeding or surgical events. Haemate P/Humate-P has a high content of the high molecular weight (HMW) VWF multimer fraction, which has been shown to be very effective in achieving haemostasis. The HMW VWF multimer pattern in Haemate P/Humate-P is more similar to that of normal human plasma (94% for Haemate P/Humate-P vs. 100% for normal human plasma) than that of other VWF/FVIII concentrates and correlates with functional VWF activities including ristocetin cofactor activity (VWF:RCo) and collagen-binding activity. The recommended dosing of Haemate P/Humate-P is based preferentially on VWF:RCo activity, which is approximately twice that of FVIII:C (2.4:1). Haemate P/Humate-P has been shown to be safe; no serious adverse events or cases of thrombosis have been observed in clinical trials and no documented cases of viral transmission in nearly three decades of clinical use. While DDAVP is effective in a large proportion of VWD patients, it may not provide adequate haemostasis in all situations. In such cases, Haemate P/Humate-P is an effective replacement concentrate for all types of VWD in both adult and paediatric patients.
G Auerswald; W Kreuz
Related Documents :
20573079 - Putting cocaine use and cocaine-associated cardiac arrhythmias into epidemiological and...
18773229 - Cardiovascular complications of cocaine: imaging findings.
2663329 - Medical complications of illicit cocaine use.
19574579 - Neurologic outcome in neonatal temporal lobe hemorrhagic venous infarcts.
21731989 - Electrocardiography series. what is the cause of the regular wide qrs complex tachycardia?
15695529 - Prevalence and risk of pulmonary embolism in patients with intracardiac thrombosis: a p...
7743529 - What happened to intravenous atenolol in acute myocardial infarction?
8888889 - Changes in the genetic expression of membrane proteins as a determinant of myocardial d...
8486879 - An audit of cardiac pacing in the elderly: effect of myocardial infarction on outcome.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Haemophilia : the official journal of the World Federation of Hemophilia     Volume:  14 Suppl 5     ISSN:  1365-2516     ISO Abbreviation:  Haemophilia     Publication Date:  2008 Nov 
Date Detail:
Created Date:  2008-09-12     Completed Date:  2008-12-05     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  9442916     Medline TA:  Haemophilia     Country:  England    
Other Details:
Languages:  eng     Pagination:  39-46     Citation Subset:  IM    
Center for Thrombosis- and Haemostasis, Prof.-Hess-Kinderklinik, Klinikum Bremen-Mitte, Bremen, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Coagulants / adverse effects,  therapeutic use*
Drug Combinations
Factor VIII / adverse effects,  therapeutic use*
Treatment Outcome
von Willebrand Diseases / drug therapy*
von Willebrand Factor / adverse effects,  therapeutic use*
Reg. No./Substance:
0/Coagulants; 0/Drug Combinations; 0/von Willebrand Factor; 9001-27-8/Factor VIII

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Diagnosis of von Willebrand disease subtypes: implications for treatment.
Next Document:  Prophylaxis in von Willebrand disease.